Cutting-Edge Biotech Startup Unveils AI-Powered Antibody Discovery Platform
Calling all biology buffs and science enthusiasts! Hold onto your lab coats, because a groundbreaking biotech startup has just revolutionized the world of antibody discovery and development. BigHat Biosciences, a San Mateo-based company, has created a platform that combines the power of artificial intelligence (AI) and synthetic biology to design the next generation of antibody therapeutics.
The brains behind this innovation are co-founders Mark DePristo and Peyton Greenside. With their backgrounds in genomics and biomedical informatics, respectively, they joined forces to build this remarkable technology. BigHat’s platform, called Milliner, uses highly automated systems and advanced machine learning models to accelerate antibody design and characterization.
So what sets BigHat apart from other companies? Well, not only does Milliner generate high-quality data for machine learning, but it also boasts an impressively rapid turnaround time. Currently, BigHat designs, creates, and tests a whopping 800 molecules per week, up from a mere 32 per week in 2020. And they’re not stopping there – they plan to double capacity several more times in the coming years.
But it’s not just about speed. BigHat’s platform allows for extensive exploration of sequence space, leading to the discovery of novel antibody candidates. By utilizing a rapid design-build-test cycle, they can probe and iterate designs more efficiently than traditional approaches. The result? Safer, more effective antibody therapeutics.
Speaking of therapeutics, BigHat aims to develop the next wave of cutting-edge antibodies, such as bispecific antibodies, antibody-drug conjugates, and single-domain antibodies. With AI/ML at their fingertips, they can optimize these antibodies for enhanced affinity and thermostability.
But what about the nitty-gritty details? How does BigHat achieve this feat? Well, their platform assesses various properties of the antibodies, including stability, solubility, yield, purity, affinity, and function. These measurements are crucial for predicting drug safety and efficacy. BigHat is also in the process of exploring in vivo properties like pharmacokinetics and pharmacodynamics, using data from their vivarium.
Excitingly, BigHat’s capabilities don’t stop at protein therapeutics. They are actively exploring how their technology can be applied to even more advanced applications, such as cellular therapies and vaccine development. The possibilities are endless!
So, what’s next for this groundbreaking biotech startup? With their state-of-the-art laboratory and multidisciplinary team, BigHat is poised for even greater success. As they continue to scale up their operations, the world can expect to see a wave of innovative antibody therapeutics hitting the market.
Now, it’s your turn! What do you think about BigHat Biosciences and their game-changing platform? Are you excited about the future of biotech? Leave a comment below and join the conversation!
IntelliPrompt curated this article: Read the full story at the original source by clicking here